COCH Stock Forecast & Price Target

Envoy Medical is attractive because its fully implanted hearing technologies address a large unmet need with differentiated design, including the FDA-approved Esteem FI-AMEI and the investigational Acclaim CI, which could broaden adoption by removing external hardware and stigma. The latest 2Q26 results showed only $51K of revenue and a $7.3M net loss, but the investment case rests on clinical momentum: the first PMA module was submitted in June 2026, the final module is targeted for 2Q27, and 12-month Stage 1 CNC scores improved to 53.2% from 39.2% at six months and 15.2% pre-implantation, with no protocol-defined serious adverse events among 10 participants. With the 56-patient pivotal trial now reaching 12-month endpoints and top-line data expected in 2Q27, the developing evidence base and Breakthrough Device status support a constructive long-term view.

Envoy Medical is viewed negatively because its valuation depends heavily on the unproven Acclaim CI, which carries only a 55% assumed U.S. approval probability and remains exposed to clinical, regulatory, and commercial failure. The company also faces acute balance-sheet pressure, with $19.7M in cash at the end of June 2026, $5.5M of operating cash burn in 2Q26, and a stated need to raise additional capital within the next 12 months absent warrant exercises. With NASDAQ minimum bid-price compliance due by November 16, 2026 and potential dilution from Series A-1 and A-2 warrants that could raise up to $48M, the stock faces meaningful financing and execution risk.